Osteoporosis - Live Search NewsSearch resultsMost don't feel osteoporosis risk - United Press International- September 17, 2008 REGINA, Saskatchewan, Sept. 17 (UPI) -- Young women and men of all ages don't see themselves at risk of osteoporosis, missing preventive measures that can lessen risk, Canadian researchers said. Researchers said that many see the risk of suffering ...http://www.upi.com/Health_News/2008/09/17/Most_dont_feel_osteoporosis_risk/UPI-20361221681... New Merck osteoporosis drug boosts bone density - Associated Press- September 17, 2008 TRENTON, N.J. (AP) -- A new type of osteoporosis drug being developed by Merck & Co. increased bone density over two years in postmenopausal women with mild osteoporosis, the company reported Tuesday. The drug, known chemically as odanacatib ...http://hosted.ap.org/dynamic/stories/M/MERCK_OSTEOPOROIS_DRUG?SITE=AP&SECTION=HOME&... Osteoporosis Drug Boosts Bone Density - Redorbit.com- September 17, 2008 Postmenopausal women suffering from osteoporosis could get relief from a new drug developed by Merck & Co. In a trial, the drug known chemically as odanacatib, improved bone density in about 5.5 percent in the lower spine. While a comparison group of ...http://www.redorbit.com/news/health/1558194/osteoporosis_drug_boosts_bone_density/index.ht... Today's Globe: osteoporosis trial, Indian generics, BPA debate, life ... - Boston Globe- September 17, 2008 Amgen's experimental bone drug reduced the risk of spinal fractures in women with osteoporosis by 68 percent in a pivotal clinical trial, a robust result that raises the probability the drug can help restore the luster of the embattled biotechnology ...http://www.boston.com/news/health/blog/2008/09/todays_globe_os_1.html Amgen osteoporosis drug denosumab cuts fracture risk, study finds - Los Angeles Times- September 17, 2008 NEW YORK -- Biotechnology company Amgen Inc. released widely anticipated data Tuesday showing its osteoporosis drug candidate denosumab dramatically cut the risk of spinal and hip fractures in postmenopausal women, compared with a placebo. Several ...http://www.latimes.com/business/la-fi-amgen17-2008sep17,0,5860145.story UPDATE 3-Amgen's osteoporosis drug data meets expectations - Reuters- September 16, 2008 BOSTON, Sept 16 (Reuters) - Amgen Inc (AMGN.O: Quote , Profile , Research , Stock Buzz ) has reported strong results from a trial of its experimental osteoporosis drug that could turn the product into a blockbuster and help offset declining sales of ...http://www.reuters.com/article/marketsNews/idUSN1638641920080916 Amgen's osteoporosis drug data meets expectations - Guardian Unlimited- September 16, 2008 BOSTON, Sept 16 (Reuters) - Amgen Inc has reported strong results from a trial of its experimental osteoporosis drug that could turn the product into a blockbuster and help offset declining sales of its flagship anemia drugs. The world's biggest ...http://www.guardian.co.uk/business/feedarticle/7802514 Merck drug increases bone density at two years - Reuters- September 16, 2008 NEW YORK, Sept 16 (Reuters) - Merck & Co's (MRK.N: Quote , Profile , Research , Stock Buzz ) experimental osteoporosis drug significantly increased bone mineral density after 24 months in a mid-stage clinical trial, improving on results seen at 12 ...http://www.reuters.com/articlePrint?articleId=USN1637464920080916 UPDATE: Amgen Bone Drug Data Comparable To Top Treatments - CNN Money- September 16, 2008 NEW YORK -(Dow Jones)- Amgen Inc. (AMGN) has released data that show its experimental bone drug denosumab is comparable to top osteoporosis treatments and will likely be a major player in a crowded market. The study's success was reported in July but ...http://money.cnn.com/news/newsfeeds/articles/djf500/200809161136DOWJONESDJONLINE000492_FOR... Amgen slated to release osteoporosis drug results - Forbes- September 16, 2008 Biotechnology company Amgen Inc. will release anticipated study results on its osteoporosis drug candidate denosumab shortly Tuesday morning, giving investors and analysts a clearer outlook on whether the treatment is a potential blockbuster. The ...http://www.forbes.com/feeds/ap/2008/09/16/ap5430709.html |